Edward J Dulac III sold $59k of NTLA
EVP, Chief Financial Officer at Intellia Therapeutics, Inc.. 6,379 shares at an average of $9.21, traded Jan 5, 2026, filed Jan 7, 2026.
Score components
- +22RoleCFO
- +7Trade size$59k at market
- 0Share of holdings soldSold 6.0% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +21.2%, 3m +36.9%, 6m +66.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-006275, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | SOpen-market sale Common Stock | -6,379 | $9.21 | $59k | 99,683 | Jan 7, 2026 |
Related signals
Other insiders at Intellia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NTLAsell Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $23k 1,864 shares | -3% | |
| 19Weak | Intellia Therapeutics, Inc. | John M Leonard President and CEO | $287k 22,675 shares | -2% | |
| 31Weak | NTLAsell Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $91k 8,111 shares | -5% | |
| 29Weak | Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $44k 2,641 shares | -4% | |
| 19Weak | Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $84k 4,677 shares | -3% | |
| 23Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $17k 1,211 shares | -1% | |
| 23Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $8,364 607 shares | -1% | |
| 40Moderate | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $96k 10,397 shares | -9% | |
| 39Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $88k 9,515 shares | -10% | |
| 58Moderate | NTLAbuy Intellia Therapeutics, Inc. | Fred E Cohen director | $1.4M 150,000 shares | +261% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.